Viracta Therapeutics
viracta.com
Actively hiring
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
Overview
Viracta Therapeutics, Inc.. Thank you for visiting the website for Viracta Therapeutics, Inc. ("Company"), a precision oncology company formerly based in Cardiff, CA. The Company is no longer operating. Any questions may be submitted by email to: [email protected].
News
Viracta Therapeutics: Navigating Strategic Liquidation
Viracta Therapeutics enters liquidation, focusing on monetizing its Nana-val oncology drug candidate and IP portfolio amid a tough biotech funding climate.
Read more
Report
Report
Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives
SAN DIEGO, Dec. 26, 2024 (GLOBE NEWSWIRE) -- Viracta Therapeutics, Inc. (Nasdaq: VIRX), a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that it
Read more
Report
Report
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma
- Patients in the Nana-val (nanatinostat in combination with valganciclovir) treatment arm achieved clinically meaningful anti-tumor responses with an overall response rate of 50% and a complete response rate of 20% in the intent-to-treat population (71%
Read more
Report
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan
--Viracta Therapeutics, Inc., a clinical-stage precision oncology company focused on the treatment and prevention of virus-associated cancers that impact patients worldwide, today announced that topline results from Stage 1 of the NAVAL-1 trial of Nana-va
Read more
Report